

August 4, 2021

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Unaudited Financial Results for the quarter ended June 30, 2021, published in Financial Express and Andhra Prabha on August 4, 2021 for your reference.

This is for your information and records.

Thanking you,

Yours faithfully,

For **Neuland Laboratories Limited**



Sarada Bhamidipati
Company Secretary

Encl : As above

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building,
Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033



EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 30.06.2021	Quarter Ended 30.06.2020	Year Ended 31.03.2021
1	Revenue from operations	20,088.67	20,542.38	93,691.31
2	Net profit for the period before tax	1,207.32	2,031.02	10,533.35
3	Net profit for the period after tax	873.45	1,516.30	8,063.07
4	Total comprehensive income for the period	871.92	1,521.16	7,906.60
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet			77,271.83 As at 31.03.2021
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)			
	(a) Basic	6.81	11.82	62.85
	(b) Diluted	6.81	11.82	62.85

Note 1: The financial results for the quarter ended 30 JUNE 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 03 August 2021.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 30.06.2021	Quarter Ended 30.06.2020	Year Ended 31.03.2021
Revenue from operations	20,088.67	20,542.38	93,691.31
Net profit for the period before tax	1,198.61	2,020.40	10,496.21
Net profit for the period after tax	864.76	1,505.68	8,029.49

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited

Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 03 August 2021



హైదరాబాద్ బుధవారం 4 ఆగస్టు 2021

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building,
Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033



EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 30.06.2021	Quarter Ended 30.06.2020	Year Ended 31.03.2021
1	Revenue from operations	20,088.67	20,542.38	93,691.31
2	Net profit for the period before tax	1,207.32	2,031.02	10,533.35
3	Net profit for the period after tax	873.45	1,516.30	8,063.07
4	Total comprehensive income for the period	871.92	1,521.16	7,906.60
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet			77,271.83 As at 31.03.2021
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)			
	(a) Basic	6.81	11.82	62.85
	(b) Diluted	6.81	11.82	62.85

Note 1: The financial results for the quarter ended 30 JUNE 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 03 August 2021.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 30.06.2021	Quarter Ended 30.06.2020	Year Ended 31.03.2021
Revenue from operations	20,088.67	20,542.38	93,691.31
Net profit for the period before tax	1,198.61	2,020.40	10,496.21
Net profit for the period after tax	864.76	1,505.68	8,029.49

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited

Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 03 August 2021